352 related articles for article (PubMed ID: 24772870)
21. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
Bhalme M; Sharma A; Keld R; Willert R; Campbell S
Eur J Gastroenterol Hepatol; 2013 May; 25(5):543-9. PubMed ID: 23337170
[TBL] [Abstract][Full Text] [Related]
22. Patients' assessment of adalimumab self-injection for Crohn's disease: a multicenter questionnaire survey (The PEARL Survey).
Hirai F; Watanabe K; Matsumoto T; Iimuro M; Kamata N; Kubokura N; Esaki M; Yamagami H; Yano Y; Hida N; Nakamura S; Matsui T
Hepatogastroenterology; 2014 Sep; 61(134):1654-60. PubMed ID: 25436358
[TBL] [Abstract][Full Text] [Related]
23. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
Emmert MY; Salzberg SP; Emmert LS; Behjati S; Plass A; Felix C; Falk V; Gruenenfelder J
Eur J Heart Fail; 2009 Nov; 11(11):1106-9. PubMed ID: 19875411
[TBL] [Abstract][Full Text] [Related]
24. Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment.
Lie MR; Peppelenbosch MP; West RL; Zelinkova Z; van der Woude CJ
Aliment Pharmacol Ther; 2014 Nov; 40(10):1202-8. PubMed ID: 25263077
[TBL] [Abstract][Full Text] [Related]
25. First case report of adalimumab-induced psoriasis in Crohn's disease.
Harris MD; Richards R
Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
[No Abstract] [Full Text] [Related]
26. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab reversed a severe lymphopenia in a patient with Crohn's disease.
Taxonera C; Mendoza JL; Ortega L; Pérez MI; Díaz-Rubio M
J Crohns Colitis; 2012 May; 6(4):488-91. PubMed ID: 22398051
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
[TBL] [Abstract][Full Text] [Related]
29. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
[TBL] [Abstract][Full Text] [Related]
30. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
[TBL] [Abstract][Full Text] [Related]
31. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
Cesarini M; Angelucci E; Foglietta T; Vernia P
J Crohns Colitis; 2011 Dec; 5(6):619-22. PubMed ID: 22115384
[TBL] [Abstract][Full Text] [Related]
32. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
[TBL] [Abstract][Full Text] [Related]
33. Listeria monocytogenes infection in Crohn's disease treated with adalimumab.
Willson KJ; Jacob A; Shetti MP; Bhatia R; Yee K; Osler W
Med J Aust; 2012 Oct; 197(8):466-7. PubMed ID: 23072245
[No Abstract] [Full Text] [Related]
34. Adalimumab for the treatment of pediatric Crohn's disease.
Nuti F; Fiorino G; Danese S
Expert Rev Clin Immunol; 2015; 11(9):963-72. PubMed ID: 26211396
[TBL] [Abstract][Full Text] [Related]
35. Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
Chiu YL; Rubin DT; Vermeire S; Louis E; Robinson AM; Lomax KG; Pollack PF; Paulson SK
Inflamm Bowel Dis; 2013 May; 19(6):1112-22. PubMed ID: 23584130
[TBL] [Abstract][Full Text] [Related]
36. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.
Mazor Y; Almog R; Kopylov U; Ben Hur D; Blatt A; Dahan A; Waterman M; Ben-Horin S; Chowers Y
Aliment Pharmacol Ther; 2014 Sep; 40(6):620-8. PubMed ID: 25039584
[TBL] [Abstract][Full Text] [Related]
37. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
Haennig A; Bonnet D; Thebault S; Alric L
Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
[No Abstract] [Full Text] [Related]
38. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells.
Dige A; Hvas CL; Deleuran B; Kelsen J; Bendix-Struve M; Dahlerup JF; Agnholt J
Scand J Gastroenterol; 2011 Oct; 46(10):1206-14. PubMed ID: 21793633
[TBL] [Abstract][Full Text] [Related]
39. [Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology].
Novacek G; Haas T; Knoflach P; Petritsch W; Tilg H; Vogelsang H; Reinisch W
Z Gastroenterol; 2013 Sep; 51(9):1101-9. PubMed ID: 23996653
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
